PD-MitoQUANT is an Innovative Medicines Initiative (IMI) research project that will improve our understanding of Parkinson’s so that better treatments can be developed in the future. The project will run for three years, receiving 4.5 million euro in funding from the EU’s Horizon 2020 programme and 2.46 million euro in-kind from European Federation of Pharmaceutical Industries and Associations (EFPIA) members and Parkinson’s UK.
The consortium involves 14 partners from 9 countries, including: RCSI (Royal College of Surgeons in Ireland), Institut du Cerveau et de la Moelle Epinière, German Center for Neurodegenerative Diseases (DZNE), Neuroscience Institute of the National Research Council, University College London, Radboud University Nijmegen Medical Centre, Centre National de la Recherche Scientifique (CNRS), SMEs (GeneXplain GmbH, Mimetas B.V., Pintail Limited), pharmaceutical companies (Teva Pharmaceutical Industries Ltd.; H. Lundbeck A/S; UCB S.A.), and a patient advocacy organization (Parkinson’s UK).
PD-MitoQUANT has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 821522. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Parkinson’s UK.
The material presented and views expressed here reflect the author’s view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.